Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

17 beta-estradiol/levonorgestrel transdermal system.

Toni M Dando1, Caroline M Perry

  • 1Adis International Inc., Yardley, Pennsylvania, USA. demail@adis.com

Treatments in Endocrinology
|August 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

The replacement of human insulin with insulin analogs: a survey conducted in france to determine current and recommended practice.

Treatments in endocrinology·2006
Same journal

Is there a rationale for insulin therapy in pre-diabetic individuals?

Treatments in endocrinology·2006
Same journal

Optimizing the benefits of bisphosphonates in osteoporosis : the importance of appropriate calcium intake.

Treatments in endocrinology·2006
Same journal

Is bio-identical hormone replacement therapy safer than traditional hormone replacement therapy?: a critical appraisal of cardiovascular risks in menopausal women.

Treatments in endocrinology·2006
Same journal

A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch.

Treatments in endocrinology·2006
Same journal

Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?

Treatments in endocrinology·2006
See all related articles

Weekly transdermal estradiol/levonorgestrel effectively treats menopausal hot flashes and improves quality of life. This hormone replacement therapy was well-tolerated, with application-site reactions being the most common side effect.

Area of Science:

  • Gynecology
  • Endocrinology
  • Pharmacology

Background:

  • Menopause is associated with vasomotor symptoms like hot flashes.
  • Hormone replacement therapy (HRT) is a common treatment for menopausal symptoms.
  • Transdermal delivery systems offer an alternative route for HRT administration.

Purpose of the Study:

  • To evaluate the efficacy and safety of a weekly transdermal estradiol/levonorgestrel system for treating menopausal vasomotor symptoms.
  • To assess the impact of this HRT on hot flash frequency, severity, endometrial hyperplasia, and quality of life.

Main Methods:

  • Randomized, double-blind, placebo-controlled trials were conducted in postmenopausal women.
  • Participants received either transdermal estradiol/levonorgestrel at various dosages or placebo.

Related Experiment Videos

  • Endpoints included weekly and daily hot flash counts, hot flash severity, endometrial hyperplasia incidence, and quality of life scores.

    • Main Results:

    • Transdermal estradiol/levonorgestrel significantly reduced weekly and daily hot flashes compared to placebo in a 12-week trial.
    • The therapy also reduced the maximal daily severity of hot flashes.
    • No endometrial hyperplasia was observed with the approved dosage of estradiol/levonorgestrel in a 12-month trial.
    • Both estradiol/levonorgestrel and estradiol improved quality of life scores over 12 months.

    Conclusions:

    • Weekly transdermal estradiol/levonorgestrel is effective in managing menopausal vasomotor symptoms.
    • The treatment demonstrates a favorable safety profile, with application-site reactions being the most common adverse event.
    • This HRT option can improve the quality of life for postmenopausal women.